Real-World Outcomes and Costs Following 6 Months of Treatment with the Long-Acting Injectable (LAI) Aripiprazole Lauroxil for the Treatment of Schizophrenia

[1]  A. Khoury,et al.  Healthcare Resource Utilization and Costs Among Patients With Schizophrenia Switching From Oral Risperidone/Paliperidone to Once-Monthly Paliperidone Palmitate: A Veterans Health Administration Claims Analysis , 2020, Current therapeutic research, clinical and experimental.

[2]  Jun Lyu,et al.  Trends in the incidence and DALYs of schizophrenia at the global, regional and national levels: results from the Global Burden of Disease Study 2017 , 2020, Epidemiology and Psychiatric Sciences.

[3]  P. Lefebvre,et al.  Real-World Analysis of Switching Patients with Schizophrenia from Oral Risperidone or Oral Paliperidone to Once-Monthly Paliperidone Palmitate , 2019, Drugs - Real World Outcomes.

[4]  P. Lefebvre,et al.  Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans , 2019, Current medical research and opinion.

[5]  Haniye Sadat Sajadi,et al.  Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017 , 2018, The Lancet.

[6]  James G. Scott,et al.  Global Epidemiology and Burden of Schizophrenia: Findings From the Global Burden of Disease Study 2016 , 2018, Schizophrenia bulletin.

[7]  M. Gore,et al.  Treatment Patterns, Healthcare Resource Utilization and Costs Among Schizophrenia Patients Treated with Long-Acting Injectable Versus Oral Antipsychotics , 2018, Advances in Therapy.

[8]  B. Shiner,et al.  Health Care Resource Utilization and Costs Associated with Transitioning to 3-month Paliperidone Palmitate Among US Veterans. , 2018, Clinical therapeutics.

[9]  J. Bobes,et al.  Baseline results from the European non-interventional Antipsychotic Long acTing injection in schizOphrenia (ALTO) study , 2018, European Psychiatry.

[10]  M. Broder,et al.  Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder , 2018, Journal of medical economics.

[11]  M. Clerici,et al.  Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly , 2017, Advances in Therapy.

[12]  P. Lefebvre,et al.  Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic , 2017, Patient preference and adherence.

[13]  M. Sajatovic,et al.  Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness , 2017, Patient preference and adherence.

[14]  C. E. Bright.  Measuring Medication Adherence in Patients With Schizophrenia: An Integrative Review , 2017, Archives of psychiatric nursing.

[15]  J. Lauriello,et al.  The Use of Long-Acting Injectable Antipsychotics in Schizophrenia: Evaluating the Evidence. , 2016, The Journal of clinical psychiatry.

[16]  C. François,et al.  The Economic Burden of Schizophrenia in the United States in 2013. , 2016, The Journal of clinical psychiatry.

[17]  C. Blanchette,et al.  Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia , 2016, Drugs in context.

[18]  C. Chiou,et al.  Global economic burden of schizophrenia: a systematic review , 2016, Neuropsychiatric disease and treatment.

[19]  John Lally,et al.  Antipsychotic medication in schizophrenia: a review. , 2015, British medical bulletin.

[20]  O. Baser,et al.  Healthcare utilization and costs of veterans health administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics , 2015, Journal of medical economics.

[21]  Foreman,et al.  The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. , 2013, JAMA.

[22]  R. Emsley,et al.  The nature of relapse in schizophrenia , 2013, BMC Psychiatry.

[23]  M. Roca,et al.  Improving Treatment Adherence in Your Patients with Schizophrenia , 2013, Clinical Drug Investigation.

[24]  P. Weiden,et al.  Long-acting injectable antipsychotics and the management of nonadherence , 2011 .

[25]  R. Conley,et al.  Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia , 2011, ClinicoEconomics and outcomes research : CEOR.

[26]  W. Gaebel,et al.  Relapse Prevention in Schizophrenia and Schizoaffective Disorder with Risperidone Long-Acting Injectable vs Quetiapine: Results of a Long-Term, Open-Label, Randomized Clinical Trial , 2010, Neuropsychopharmacology.

[27]  D. Ford,et al.  Health insurance coverage among persons with schizophrenia in the United States. , 2010, Psychiatric services.

[28]  S. Simpson,et al.  Switching stable patients with schizophrenia from depot and oral antipsychotics to long‐acting injectable risperidone: efficacy, quality of life and functional outcome , 2010, Human psychopharmacology.

[29]  P. Weiden,et al.  The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. , 2009, The Journal of clinical psychiatry.

[30]  H. Ascher-Svanum,et al.  Cost Effectiveness and Resource Allocation Open Access Methodological Issues in Assessing Changes in Costs Pre-and Post-medication Switch: a Schizophrenia Study Example , 2022 .

[31]  M. Valenstein,et al.  Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review. , 2006, The Journal of clinical psychiatry.

[32]  R. Kessler,et al.  The economic burden of schizophrenia in the United States in 2002. , 2005, The Journal of clinical psychiatry.

[33]  P. Weiden,et al.  Partial compliance and risk of rehospitalization among California Medicaid patients with schizophrenia. , 2004, Psychiatric services.

[34]  R. Deyo,et al.  Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. , 1992, Journal of clinical epidemiology.

[35]  Julie Kreyenbuhl,et al.  The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. , 2010, Schizophrenia bulletin.

[36]  J. McGrath,et al.  Comprehensive care of schizophrenia: A textbook of clinical management , 2001 .